Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer

1 Jan 2000

Abstract excerpt

MDM2 is one of the downstream target genes for transcriptional activation by the product of the p53 tumor-suppressor gene. Transactivation of MDM2 gene expression is represented by the presence of a functional p53 protein. We hypothesized that MDM2 mRNA expression may be a more suitable prognostic factor than p53 or MDM2 protein expression and p53 gene mutations. In this study, expression of MDM2 mRNA, p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10861503
DOI: 10.1002/1097-0215(20000520)89:3<265::aid-ijc9>3.0.co;2-n

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancerPMID 10861503Read ↗

Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.Semantic proximity Read ↗

MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulationSemantic proximity Read ↗

Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.Semantic proximity Read ↗

MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese.Semantic proximity Read ↗

TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.Semantic proximity Read ↗

MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical TrialsSemantic proximity Read ↗

Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.Semantic proximity Read ↗

mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations.Semantic proximity Read ↗

MDM2 Oncogene as a Novel Target for Human Cancer TherapySemantic proximity Read ↗

p53-Independent Activities of MDM2 and Their Relevance to Cancer TherapySemantic proximity Read ↗

Recent Advances in Validating MDM2 as a Cancer TargetSemantic proximity Read ↗

Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.